- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
This appraisal has been split into the adult and paediatric populations. ID6486 will continue as the evaluation of budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in adults 18+ years. The evaluation of budesonide oral suspension inducing and maintaining remission of eosinophilic oesophagitis in children 2-18 years will progress under ID6761.
- Process:
- STA Standard
- ID number:
- 6760
Email enquiries
If you have any queries please email Scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 May 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 08 May 2026 | This appraisal has been split into the adult and paediatric populations. - Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual